Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Income-Before-Tax" stands at 31.50 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Johnson & Johnson's third quarter result of 7.49 Billion USD for the item "Income Before Tax" represents an increase of 15.44 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 7.49 Billion USD for the item "Income Before Tax" represents an increase of 124.48 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 31.50 Billion USD for the item "Income Before Tax" represents an increase of 15.19 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 78.72 percent compared to the value the year prior.
The 1 year change in percent is 78.72.
The 3 year change in percent is 40.89.
The 5 year change in percent is 65.21.
The 10 year change in percent is 73.65.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Income Before Tax | 905,699,262,464.00 |
![]() | AbbVie Inc - Income Before Tax | 399,570,305,024.00 |
![]() | Roche Holding AG - Income Before Tax | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Income Before Tax | 280,205,508,085.11 |
![]() | Novartis AG - Income Before Tax | 255,096,620,580.91 |